Cited 8 times in
Preoperative fecal elastase-1 is a useful prognostic marker following curative resection of pancreatic cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박준성 | - |
dc.contributor.author | 윤동섭 | - |
dc.contributor.author | 임진홍 | - |
dc.date.accessioned | 2018-07-20T07:47:17Z | - |
dc.date.available | 2018-07-20T07:47:17Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 1365-182X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/160521 | - |
dc.description.abstract | BACKGROUND: The clinical relevance of fibrosis with regard to tumor progression is supported by the correlation between fibrosis and poor outcomes. Fecal elastase-1 (FE-1) level has been used to assess exocrine dysfunction of the pancreas and to predict pancreas fibrosis. The aim of this study was to assess the impact of FE-1 on the survival of pancreatic cancer patients. METHODS: Between January 2006 and December 2014, 136 patients with pancreatic adenocarcinoma underwent R0 resection at Gangnam Severance Hospital, Korea. Preoperative FE-1 levels were available in 94 patients who were enrolled in the study. Patients were classified into two groups according to preoperative FE-1: "normal" (≥200 μg/g) or "reduced" (<200 μg/g). RESULTS: Median preoperative FE-1 level was 130.1 μg/g (IQR 32.0; 238.3). 62 patients (66.0%) had reduced pancreatic function and 32 patients (34.0%) had normal pancreatic function. The two groups had significantly different disease-free survival (P < 0.001). On multivariate analysis, normal FE-1, no lymph node metastasis and completion of adjuvant chemotherapy were found to be independent prognostic factors for better DFS (P = 0.001, P = 0.017, P = 0.038, respectively). CONCLUSION: FE-1 is a simple and non-invasive predictive clinical marker for prognosis of pancreatic cancer after attempted curative resection. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | England | - |
dc.publisher | 1477-2574 | - |
dc.relation.isPartOf | HPB | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenocarcinoma/enzymology* | - |
dc.subject.MESH | Adenocarcinoma/mortality | - |
dc.subject.MESH | Adenocarcinoma/secondary | - |
dc.subject.MESH | Adenocarcinoma/surgery* | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Biomarkers, Tumor/analysis* | - |
dc.subject.MESH | Chemotherapy, Adjuvant | - |
dc.subject.MESH | Chi-Square Distribution | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Down-Regulation | - |
dc.subject.MESH | Feces/enzymology* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fibrosis | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Lymphatic Metastasis | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Multivariate Analysis | - |
dc.subject.MESH | Neoadjuvant Therapy | - |
dc.subject.MESH | Pancreatectomy*/adverse effects | - |
dc.subject.MESH | Pancreatectomy*/mortality | - |
dc.subject.MESH | Pancreatic Elastase/analysis* | - |
dc.subject.MESH | Pancreatic Function Tests | - |
dc.subject.MESH | Pancreatic Neoplasms/enzymology* | - |
dc.subject.MESH | Pancreatic Neoplasms/mortality | - |
dc.subject.MESH | Pancreatic Neoplasms/pathology | - |
dc.subject.MESH | Pancreatic Neoplasms/surgery* | - |
dc.subject.MESH | Predictive Value of Tests | - |
dc.subject.MESH | Proportional Hazards Models | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Preoperative fecal elastase-1 is a useful prognostic marker following curative resection of pancreatic cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Surgery | - |
dc.contributor.googleauthor | Lim JH | - |
dc.contributor.googleauthor | Park JS | - |
dc.contributor.googleauthor | Yoon DS | - |
dc.identifier.doi | 10.1016/j.hpb.2016.12.007 | - |
dc.contributor.localId | A01672 | - |
dc.contributor.localId | A02548 | - |
dc.contributor.localId | A03411 | - |
dc.relation.journalcode | J03345 | - |
dc.identifier.eissn | 1477-2574 | - |
dc.identifier.pmid | 28286044 | - |
dc.identifier.url | https://www.clinicalkey.com/#!/content/medline/2-s2.0-28286044 | - |
dc.contributor.alternativeName | Park, Joon Seong | - |
dc.contributor.alternativeName | Yoon, Dong Sup | - |
dc.contributor.alternativeName | Lim, Jin Hong | - |
dc.contributor.affiliatedAuthor | Park, Joon Seong | - |
dc.contributor.affiliatedAuthor | Yoon, Dong Sup | - |
dc.contributor.affiliatedAuthor | Lim, Jin Hong | - |
dc.citation.volume | 19 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 388 | - |
dc.citation.endPage | 395 | - |
dc.identifier.bibliographicCitation | HPB, Vol.19(5) : 388-395, 2017 | - |
dc.identifier.rimsid | 44255 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.